Last Update 25 Aug 26
Fair value Increased 9.02%C79: 2027 Revenue Guidance Will Support Higher Profitability Assumptions
The analyst price target for Chrysos has been revised from A$8.62 to A$9.39, with analysts pointing to updated assumptions around revenue growth, profit margins and future P/E expectations as the key drivers of this change.
What’s in the News for Chrysos
- Chrysos Corporation Limited issued earnings guidance for 2027, with expected revenue in a range of $108 million to $118 million. Source: Company guidance.
- The new 2027 revenue guidance provides a reference point that analysts can use when updating assumptions for Chrysos on revenue, profit margins and future P/E expectations. Source: Company guidance.
- Investors tracking Chrysos now have a specific revenue range for 2027, which can be compared with current analyst price targets and valuation frameworks. Source: Company guidance.
Valuation Changes for Chrysos
- Fair Value has moved from A$8.62 to A$9.39, which represents a moderate uplift in the analyst assessment of Chrysos.
- The Discount Rate has adjusted from 6.88% to 7.46%, indicating a slightly higher required return being applied to Chrysos in the model.
- The Revenue Growth assumption has shifted from 33.21% to 25.71%, which represents a meaningful step down in the growth rate used in forecasts.
- Net Profit Margin has moved from 11.09% to 13.43%, reflecting a higher profitability assumption for Chrysos.
- The Future P/E has been revised from 72.63x to 57.50x, which indicates a lower valuation multiple being used in the updated model.
Catalysts
About Chrysos
Chrysos provides PhotonAssay units and services for mineral analysis, primarily to mining companies and laboratory partners.
What are the underlying business or industry changes driving this perspective?
- Growing global deployment of PhotonAssay units, including new regions such as Chile and Suriname, increases the installed base that feeds into minimum monthly assay payments, supporting future revenue and EBITDA.
- The mix of revenue toward minimum monthly assay payments at 85% of PhotonAssay income provides higher visibility, while additional assay charges linked to sample volumes give upside potential to earnings as utilization changes.
- Expansion across the Americas and EMEA with a hub model and shared maintenance resources is expected to create operating efficiencies. This has the potential to support gross margin and net margin over time as the fleet grows.
- Development of the next generation XN unit, designed for lower installation, transport and maintenance requirements, points to a pathway for reduced unit level costs. This could support margins and cash generation per unit.
- A PhotonAssay unit cost profile just under A$4 million plus around A$400,000 of spares for assets expected to generate in excess of A$20 million in lifetime cash suggests unit economics that can support revenue and operating cash flow as more units are deployed.
Assumptions
How have these above catalysts been quantified?
- Analysts are assuming Chrysos's revenue will grow by 25.7% annually over the next 3 years.
- Analysts assume that profit margins will increase from 2.0% today to 13.4% in 3 years time.
- Analysts expect earnings to reach A$23.5 million (and earnings per share of A$0.2) by about August 2029, up from A$1.8 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting A$31.4 million in earnings, and the most bearish expecting A$14.4 million.
- In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 57.8x on those 2029 earnings, down from 481.7x today. This future PE is greater than the current PE for the AU Professional Services industry at 17.0x.
- Analysts expect the number of shares outstanding to remain consistent over the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 7.46%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?
- The business model leans heavily on minimum monthly assay payments as the backbone of revenue, so any long term slowdown in exploration activity or mine production, particularly across international regions that now represent 65% of total revenue, could reduce assay volumes and weaken the stability of PhotonAssay revenue and EBITDA.
- Geographic expansion into new markets such as Chile and Suriname increases complexity in tax, regulation and operations. Setbacks in new country entries or higher than expected ongoing costs for advisers, maintenance hubs and local teams could erode gross margins and net margins over time.
- The expectation that each PhotonAssay unit will generate in excess of A$20 million of lifetime cash relies on sustained utilisation and customer retention. If mining customers shift assay methods or reduce usage, unit economics could deteriorate and reduce long term operating cash flow and earnings.
- The next generation XN unit is intended to lower installation, transport and maintenance requirements. Delays in development, higher build costs or weaker customer acceptance could limit the expected improvement in direct costs per unit and weigh on future gross margin and cash generation per unit.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The analysts have a consensus price target of A$9.39 for Chrysos based on their expectations of its future earnings growth, profit margins and other risk factors.
- In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be A$175.0 million, earnings will come to A$23.5 million, and it would be trading on a PE ratio of 57.8x, assuming you use a discount rate of 7.5%.
- Given the current share price of A$7.4, the analyst price target of A$9.39 is 21.2% higher.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on Chrysos?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Comments
0 commentsDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.
